Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1/2
- “A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus”In the company’s words, NCT06625671 on ClinicalTrials.gov
Other drugs for Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up1
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jun 2027 | A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026